VV-14300 for the Treatment of Type 1 Diabetes
NCT07831798
Autoimmune Diseases, Diabetes Mellitus
Toronto, Canada
View Trial DetailsNCT Number: NCT06586879
This study aimed to assess the prevalence of psychiatric comorbidities in children and adolescents with diabetes mellitus type 1.
Assessing the impact of diabetes mellitus type 1 on quality of life. And determine the effect of associated factors on the development of psychiatric comorbidities and on quality of life in diabetes mellitus type 1.
Trial opening soon.
Get Notified8 year–15 year
All sexes
Observational
Type 1 diabetes mellitus (TDM) is a chronic autoimmune disease. that affected carbohydrate metabolism and caused by insulin insufficiency resulting in increased blood glucose. It's one of the most common endocrine and metabolic conditions in childhood. There's 9 million people live with T1DM worldwide according to International Diabetes Federation. In Egypt, 1 in 98 families are impacted and the disease is growing at 6.7% each year. Living with T1DM has been associated with a significant impact on a person's social, mental, and psychological quality of life (QoL). as the individual must adopt blood glucose monitoring, use of injections or diabetes technology for insulin regulation, diet restrictions, and exercise. Also, there's increased risk of developing micro-and macro-vascular complications that result in morbidity and mortality in Long-term uncontrolled DM. therefore, these children and adolescents with T1DM have an increased risk of psychiatric comorbidities like depression, anxiety and sleep disorders, depression is one of the most common disorders. They appear to have a greater incidence of depression, anxiety and poor health-related quality of life (HRQoL) compared to their healthy peers. This is associated with suboptimal diabetes outcomes and better metabolic control has been found to correlate with better quality of life. This occurs especially when diagnosed at earlier age of onset, history of severe hypoglycemia and chronic hyperglycemia. There are no available studies that assess the presence of psychiatric comorbidities in T1DM in our locality.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 2 years
This outcome will be measured using:
The Kiddie-Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime (K-SADS-PL) version
Time frame: 2 years
this outcome will be measured using:
Time frame: 2 years
This outcome will be measured using:
Pediatric quality of life inventory 4.0 genetic Core scale.
Trial opening soon.
Get NotifiedAssiut University
Other
Psychiatric Comorbidities in Children and Adolescent Patients with Diabetes Mellitus Type 1.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07831798
Autoimmune Diseases, Diabetes Mellitus
Toronto, Canada
View Trial DetailsNCT07829302
Autoimmune Diseases, Diabetes Mellitus
Melbourne, Australia
View Trial DetailsNCT07325201
Acid-Base Imbalance, Acidosis
Minneapolis, Minnesota, United States
View Trial DetailsNCT07785037
Autoimmune Diseases, Diabetes Mellitus
View Trial Details